GlassScriptPhysician profile
Michael P Barker
NPI 1750701355
$6,557.81
in general payments reported to CMS, 2019-2025
34 companies · $1,819 in 2025
The $1,819 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $223 · 2022: $1,215 · 2023: $1,921 · 2024: $1,184 · 2025: $1,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,923.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,504.96 | 2020-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $950.83 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $543.80 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $313.80 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $309.23 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.55 | 2022-2025 | Xifaxan, Trulance |
| Micro-Tech Endoscopy USA, INC. | $192.32 | 2024 | |
| Madrigal Pharmaceuticals | $177.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $163.58 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $137.34 | 2019-2022 | |
| Genzyme Corporation | $110.35 | 2024-2025 | |
| Fujifilm Healthcare Americas Corporation | $96.63 | 2023 | Utaswako Afp-L3 |
| Phathom Pharmaceuticals, INC. | $87.32 | 2023-2025 | Voquezna |
| Celltrion USA INC. | $85.39 | 2024-2025 | Vegzelma |
| Olympus Corporation of The Americas | $71.41 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $68.70 | 2022 | |
| Qol Medical, LLC | $61.44 | 2023-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $61.30 | 2024-2025 | Dupixent |
| Redhill Biopharma INC. | $58.53 | 2022-2023 | Talicia |
| Gilead Sciences, INC. | $49.03 | 2025 | |
| Mallinckrodt Hospital Products INC. | $47.90 | 2022-2023 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $41.52 | 2024-2025 | Bylvay, Iqirvo |
| Braintree Laboratories, INC. | $39.26 | 2022-2024 | Suflave, Sutab |
| Medtronic, INC. | $32.32 | 2024 | Interstim |
| Pharmacosmos Therapeutics INC. | $24.01 | 2023 | Monoferric |
| Novo Nordisk INC | $19.99 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $18.97 | 2025 | Zenpep |
| Amgen INC. | $17.56 | 2023 | Amjevita, Avsola |
| Evoke Pharma, INC. | $15.40 | 2022 | |
| Merck Sharp & Dohme LLC | $15.17 | 2023 | Dificid |
| Ferring Pharmaceuticals INC. | $14.81 | 2024 | Rebyota |
| Lilly USA, LLC | $13.48 | 2025 | Omvoh |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,142.76 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.